eribulin
eribulin: sourced relationships with 1 company · 12 clinical trials tracked · 1 FDA decision.
eribulin evidence translation
What we can confirm
1 FDA record · 12 tracked trials
What it means
What to watch
Prepared research question
How could eribulin → RDY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 4 study sponsors
Related indications
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| DR REDDYS LABORATORIES LTD (RDY) Reported 2025-07-03 · Current development: unknownSource | Approved |
| DR REDDYS LABORATORIES LTD (RDY) Reported 2025-07-03 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (12)showing 10 most recent
A Multicenter, Randomized, Double-Blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX22 in Combination With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy in Locally Advanced Unresectable and/or Metastatic HER2-Positive Breast Cancer Previously Treated With HER2 ADC
Primary endpoint: Objective response rate (ORR) assessed by the blinded independent central review (BICR) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Protocol ASPEN-09-03: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Participants With Metastatic HER2-Positive Breast Cancer, a Substudy Under Master Protocol ASPEN-09: A Phase 1b/2, Multicenter, Multi Arm Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies
Primary endpoint: Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment
A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease
Primary endpoint: Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
A Phase I Trial of Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Primary endpoint: Number of adverse events experienced by participants
A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer
Primary endpoint: Occurrence of treatment emergent adverse events (TEAEs), adverse events of special interest (AESIs), treatment emergent serious adverse events (SAEs)
A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment
Primary endpoint: Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR)
A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adults With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas (INVINCIBLE-3)
Primary endpoint: Overall Survival (OS)
A Phase 1a/1b Study of ELVN-002 Combined With Trastuzumab in Advanced Stage HER2+ Solid Tumors, and ELVN-002 Combined With Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast Cancer
Primary endpoint: Incidence of dose limiting toxicities (DLTs; Phase 1a only)
The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma
Primary endpoint: Clinical Benefit Rate (CBR) by RECIST v1.1 in combination therapy arm
Assessing the Impact of Scalp Cooling in With Metastatic Breast Cancer
Primary endpoint: Hair Loss Rate
Frequently asked questions
Which companies have sourced relationships with eribulin?
eribulin has dated SEC/FDA relationship records for DR REDDYS LABORATORIES LTD.
How many clinical trials involve eribulin?
BioSniper tracks 12 clinical trials involving eribulin.
What is eribulin's latest FDA decision?
The most recent tracked FDA decision for eribulin is Approval, dated July 3, 2025.